GlassScriptPhysician profile
Adey Berhanu
NPI 1417246091
$23,720.05
in general payments reported to CMS, 2019-2025
19 companies · $18.64 in 2025
The $18.64 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $1,125 · 2021: $5,540 · 2022: $9,965 · 2023: $1,603 · 2024: $4,398 · 2025: $18.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,922 · Travel and Lodging: $1,036 · Honoraria: $563 · Food and Beverage: $474 · Education: $25.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,921.79 |
| Travel and Lodging | $1,035.69 |
| Honoraria | $562.50 |
| Food and Beverage | $474.45 |
| Education | $25.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17,401.48 | 2019-2023 | Krystexxa |
| Sobi, INC | $4,384.37 | 2019-2024 | |
| Pacira Pharmaceuticals Incorporated | $830.46 | 2023-2025 | Iovera |
| Amgen INC. | $245.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $148.95 | 2019-2022 | |
| Janssen Biotech, INC. | $146.47 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $120.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $112.10 | 2019 | |
| Abbvie INC. | $85.22 | 2019-2022 | |
| Ucb, INC. | $50.12 | 2019 | |
| Radius Health, INC. | $45.02 | 2019 | |
| Pfizer INC. | $24.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.57 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2023 | Lupkynis |
| Gilead Sciences, INC. | $19.27 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.40 | 2019 | |
| Sebela Pharmaceuticals INC. | $15.66 | 2019 | |
| Hikma Pharmaceuticals USA | $15.66 | 2019 | |
| Lilly USA, LLC | $14.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adey Berhanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.